Enlicitide, an oral cholesterol-lowering drug, is getting noticed by health professionals as an option for patients who want an injection-free treatment. Merck has also achieved a key step in its cholesterol drug pipeline, while a cholesterol medicine developed with McMaster University research has cleared regulatory approval in Canada.

Health outlets this week looked into how exercise changes LDL cholesterol readings, and TODAY.com cautioned readers against following cholesterol advice circulating on social media. LDL cholesterol is widely known as the 'bad' type because high levels are linked to heart disease.